“Lupin has clearly broken away from the rest to emerge as the 5th largest and the fastest growing Top 10 Generic Business in the US (in Rx's) - the only Indian pharma major to ever achieve this feat”
	Mrs. Vinita Gupta Group President & CEO Lupin Pharmaceuticals Inc

Lupin Pharmaceutical Inc. (LPI) is the Company’s US subsidiary. In a short span, Lupin has firmly established in the minds of pediatricians and pharmacists through its Brand and Generic business, respectively. Lupin’s entry as a finished dosage player in the US I 2003 was initiated with the launch of Cefuroxime Axetil. The Company set the ball rolling with the introduction of its first brand Suprax in 2004, and its generic business gained momentum in 2005.

Lupin's Advanced Markets business in US and Europe has continued its upward growth momentum during the year with total sales of INR 18,570 million, up from INR 13,567 million during the previous fiscal, a growth of 37%. The Company's Formulations sales in the US market grew to INR 16,497 million during FY 2010, up from INR 11,894 million during the previous year. The Company continues to register impressive growth in the European Market where Formulations sales grew 36%, to INR 1,395 million for FY 2010 up from INR 1,023 million during FY 2009.

Riding high on the momentum built up in our Branded Business and sustained, consistent growth in Generics, Lupin's Formulations business in the US emerged as the key growth driver for the Company, recording sales of INR 16,497 million during FY 2010 as compared to INR 11,894 million in FY 2009, up 39%.

For more information log on to www.lupinpharmaceuticals.com